Changes in Hong Kong stocks | Nuochengjianhua (09969) rose more than 4% to turn a loss into profit in the first three quarters and continued to release obutinib, the core product

The Zhitong Finance App learned that Nuocheng Jianhua (09969) rose by more than 4%. As of press release, it had risen 5.08% to HK$14.49, with a turnover of HK$38.642 million.

According to the news, recently, Nuochengjianhua announced the results for the first three quarters of 2026. The company's total revenue was 2,099 billion yuan, an increase of 88.21% over the same period last year, of which pharmaceutical sales revenue was 1,449 billion yuan, an increase of 41.47% over the same period last year. The main reason for the increase in revenue was the continued release of the core product obutinib, additional sales contributions of tamxitumab and zoletriptinib, and completion of subsequent milestone deliveries in the licensing agreement between the company and Zenas BioPharma, Inc. Net profit attributable to shareholders of listed companies was approximately 656 million yuan, turning a year-on-year loss into a profit.

From January to September 2026, the net cash flow from the company's operating activities was 220 million yuan, which changed from negative to positive over the previous year. Mainly due to increased revenue from drug sales and licensing, the company's operating cash flow situation continued to improve.